Clinical significance of incidental FDG uptake in the prostate gland detected by PET/CT

Basit Öğe Kaydı
dc.contributor.authorSahin, Ertan
dc.contributor.authorElboga, Umut
dc.contributor.authorKalender, Ebuzer
dc.contributor.authorBasibuyuk, Mustafa
dc.contributor.authorDemir, Hasan Deniz
dc.contributor.authorCelen, Yusuf Zeki
dc.date.accessioned2024-09-18T20:55:29Z
dc.date.available2024-09-18T20:55:29Z
dc.date.issued2015
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractThe value of FDG-positron emission tomography/computed tomography (PET/CT) for detecting prostate cancer is unknown. We aimed to investigate the clinical value of incidental prostate FDG uptake on PET/CT scans. We reviewed 6128 male patients who underwent FDG-PET/CT scans and selected cases that reported hypermetabolic lesion in the prostate. The patients who have prior history of prostate carcinoma or prostate surgery were excluded from the study. We have analyzed the correlation between PET/CT findings and serum prostate-specific antigen (PSA) levels, imaging (USG), urological examinations and biopsy. Incidental 18F-FDG uptake of the prostate gland was observed in 79 patients (1.3%). While sixteen of them were excluded due to inadequate clinical data, the remaining 63 patients were included for further analysis. The patients were divided into two groups; 8 patients (12.7%) in the malignant group and 55 patients (87.3%) in the benign group. The SUVmax values were not significantly different between the two groups. In 6 (75%) patients with prostate cancer, FDG uptake was observed focally in the peripheral zone of the prostate glands. There was no significant correlation between the SUVmax and the PSA levels. Incidental 18F-FDG uptake in the prostate gland is a rare condition, but a substantial portion of it is associated with the cancer. Benign and malignant lesions of the prostate gland in FDG-PET/CT imaging could not be reliably distinguished. The peripheral focally FDG uptake of prostate glands should be further examined with the clinical and labaratory evaluations.en_US
dc.identifier.endpage10585en_US
dc.identifier.issn1940-5901
dc.identifier.issue7en_US
dc.identifier.pmid26379847en_US
dc.identifier.scopus2-s2.0-84940706300en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage10577en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11866
dc.identifier.volume8en_US
dc.identifier.wosWOS:000361557500034en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherE-Century Publishing Corpen_US
dc.relation.ispartofInternational Journal of Clinical and Experimental Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectProstate canceren_US
dc.subject18F-fluorodeoxyglucoseen_US
dc.subjectpositron emission tomography/computed tomographyen_US
dc.titleClinical significance of incidental FDG uptake in the prostate gland detected by PET/CTen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu